Clinical Trial Update

AI SummaryClose X

Coiled Therapeutics plc announced positive clinical trial results for its TACC3 inhibitor, AO-252, showing an 80% Clinical Benefit Rate in the Twice-Daily dosing cohort, a significant improvement over the 40% seen with Once-Daily dosing, with durable responses exceeding six months. The drug maintained a benign safety profile with no serious adverse events, and the Maximum Tolerated Dose has not been reached, allowing for continued dose escalation. The company is accelerating its transition to dose expansion cohorts in ovarian and prostate cancers, targeting 40 patients by Q3 2026, and is also developing combination therapy protocols. Key milestones for 2026 include completing Phase I dose escalation in H1, introducing a next-generation formulation mid-year, and initiating combination therapy studies in Q3.

Disclaimer*

UK 100

Latest directors dealings